This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Rare Disease Animal Model Development Service
Introduction
Facing the challenge of limited patient samples and complex preclinical development for rare diseases? BioVenic's integrated rare disease animal model development services provide the solution. BioVenic offers expert custom model generation (leveraging cutting-edge gene editing), rigorous validation, and comprehensive preclinical non-GLP study execution. This end-to-end service ensures you access high-quality, phenotypically accurate animal models, dramatically simplifying your path to actionable scientific data.
BioVenic Rare Disease Animal Model Development Services
Rare Disease Animal Model Development
BioVenic specializes in designing and generating bespoke rare disease animal models meticulously tailored to your unique genetic, pathological, and experimental needs. Recognizing that genetic similarity is key for translational success, we utilize state-of-the-art technologies combined with microinjection to achieve precise genetic modifications. BioVenic's expertise covers a wide range of model types:
Knockout (KO) / Knock-in (KI) Models: Precise deletion or substitution of disease-causing genes (e.g., F8-KO for Hemophilia).
Conditional Models: Utilizing Cre-LoxP systems for tissue/stage-specific studies.
Humanized Models: Introducing human gene segments or regulatory elements (e.g., human TTR gene) into the animal genome to enhance predictive relevance.
Rare Disease Animal Model Validation and Characterization
The utility of any animal model hinges on its fidelity to the human condition. BioVenic performs meticulous validation to confirm both the genetic modification and the phenotypic expression of the disease. This critical step ensures the model is fit for purpose. Common validation methods include:
Genetic Confirmation: PCR/qPCR, Sanger/Next-Generation Sequencing (NGS), and Southern Blotting to verify the precise genetic change.
Molecular Analysis: Western Blot, ELISA, and qPCR to confirm changes in the expression level and function of the target protein or gene.
Phenotypic Characterization: Histopathology (H&E and specialized staining), immunohistochemistry (IHC), clinical chemistry, and functional assays (e.g., motor function tests for ALS/DMD models) to assess disease-relevant signs.
Specialized Rare Disease Animal Model Biospecimen Collection Services
BioVenic offers expert and controlled collection of diverse biospecimens from our established rare disease models, essential for molecular and pathological analysis.
Tissues/Organs: Muscle tissue (for DMD), nervous tissue (for ALS), liver (for GSD Ia), bone/cartilage.
Fluids: Whole blood, plasma, serum, urine, and cerebrospinal fluid (CSF).
Isolated Cells: Primary cell culture from diseased tissues or peripheral blood cells.
Preclinical Research and Downstream Assays on Rare Disease Animal Models
Leveraging our validated models, BioVenic conducts a broad range of non-GLP preclinical studies to support your discovery phase:
Target Assessment: Systematic evaluation of gene and protein targets.
Compound Efficacy Screening: In vivo evaluation of novel molecules.
Pharmacokinetic (PK) and Pharmacodynamic (PD) Studies: Detailed analysis of drug exposure and biological response.
Mechanism of Disease Elucidation: Deep mechanistic studies to uncover early pathogenesis.
Biomarker Discovery: Identification and validation of predictive and prognostic disease markers.
Explore BioVenic's investigative modalities:
- Animal Behavioral Analysis
- Animal Histopathology Service
- Preclinical Animal Pharmacodynamics (PD) Study
- Preclinical Animal Pharmacokinetics (PK) Study
- Animal Cell Biology Service
- Animal Imaging Service
Development Workflow for a Rare Disease Animal Model
Rare Disease Animal Models and Application Fields
Table. 1 Common Rare Disease Animal Models and Application Fields
| Rare Disease Model | Animal Type | Model Generation Principle | Primary Application Area |
|---|---|---|---|
| ALS (Amyotrophic Lateral Sclerosis) | Mouse, Rat | Transgene/Point Mutation | Mechanism & Target Assessment |
| Hereditary TTR Amyloidosis | Humanized Mouse | Human Gene Replacement | Drug Efficacy & TTR Targeting Studies |
| Duchenne Muscular Dystrophy (DMD) | Mouse | Gene Modification (Dmd gene) | Preclinical Efficacy, Pathology Studies |
| Hemophilia A/B | Mouse | Gene Knockout (F8-KO, F9-KO) | Coagulation Factor Evaluation |
| AD Hypophosphatemic Rickets (ADHR) | Mouse | Point Mutation | Metabolic Pathway Analysis |
| Glycogen Storage Disease Type Ia (GSD Ia) | Mouse | Conditional Knockout | Metabolism and Intervention Studies |
| IgG4-Related Disease (IgG4-RD) | Mouse | Point Mutation | Immunopathology & Mechanistic Research |
Advantages of BioVenic Rare Disease Animal Model Development Service
Strategic Project Customization
BioVenic transcends a catalog approach by offering highly strategic, customized project design. Based on your research objectives, we analyze the genetic and pathological characteristics of the rare disease to select the most relevant animal species, the optimal genetic modification technique, and a tailored experimental protocol. This meticulous planning, informed by a deep understanding of model characteristics (Natural, Gene-edited, Induced, Xenograft), is critical for delivering scientific clarity and reliable data.
Comprehensive Validation and Detection Capabilities
BioVenic ensures the success of your project by integrating model generation with a powerful analytical platform. We not only build models but also provide the critical tools for their validation and subsequent sample analysis.
One-Stop Service
BioVenic is your single scientific partner, offering a streamlined, end-to-end service that encompasses model design, creation, rigorous validation, colony management, and sophisticated in vivo study execution. By consolidating these complex steps, we ensure continuity, reduce project management overhead, and accelerate your timeline from concept to data delivery.
Case Study: Specialized SMA Modeling & Neurodegenerative Efficacy Evaluation
Our facility provides a high-performance transgenic model of Spinal Muscular Atrophy (SMA). This service offers a standardized environment for evaluating neurodegenerative therapies by delivering a verified phenotype of progressive motor neuron loss and skeletal muscle atrophy. We ensure rigorous model validation through Western blot analysis to quantify SMN protein levels and a comprehensive battery of phenotypic assessments, including growth curve monitoring, postural analysis, and righting reflex testing to evaluate motor function. Furthermore, our integrated pathology suite provides high-resolution immunofluorescence staining to quantify motor neuron depletion in the spinal cord and denervation.
Fig. 1 Significant motor neurons loss is observed in thoracic spinal cord segments in the Smn2B/- mouse model.1
FAQs
How do you ensure your models accurately reflect the human rare disease?
We prioritize high genetic and phenotypic fidelity. We utilize techniques like Knock-in or Humanization to precisely replicate the patient's specific pathogenic mutation, which is critical for maximizing the model's predictive power for non-GLP efficacy studies.
Can you perform drug efficacy testing on the models you generate?
Yes. We offer comprehensive, non-GLP preclinical in vivo efficacy studies. This includes experimental design, compound administration, detailed phenotypic monitoring, and full sample analysis (histology, biochemistry, PK/PD) performed within our facility.
What type of quality control is performed on the animal colonies?
Our colonies undergo rigorous genetic screening to confirm the stability of the modification. We monitor the colony's health and phenotypic consistency throughout the breeding and study phases.
Contact Us
The journey in rare disease research requires both precision and speed. BioVenic's platform delivers high-quality, validated, and customized animal models alongside expert preclinical study execution-making your complex research simpler and more efficient. We are committed to generating the robust scientific evidence you need to drive your discovery forward. Ready to leverage our scientific excellence to accelerate your rare disease project? Contact us today for a consultation and a tailored quote.
Reference
- Woschitz, Victoria, et al. "Mouse models of SMA show divergent patterns of neuronal vulnerability and resilience." Skeletal muscle 12.1 (2022): 22. https://doi.org/10.1186/s13395-022-00305-9. Distributed under Open Access license CC BY 4.0. Figure 2(A) was extracted.